Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

AAA, 2009 - aspirin vs placebo

JPAD, 2008 - aspirin vs no treatment

POPADAD aspirin, 2008 - aspirin vs placebo

CHARISMA, 2006 - clopidogrel + aspirin vs aspirin

Women’s Health Study, 2005 - aspirin vs placebo

Primary Prevention Project, 2001 - aspirin vs no treatment

Thrombosis Prevention trial (W alone), 1998 - warfarin vs placebo

HOT, 1998 - aspirin vs placebo

Thrombosis Prevention trial (W+A), 1998 - warfarin + aspirin vs placebo

Thrombosis Prevention Trial, 1998 - aspirin vs placebo

CAPRIE, 1996 - clopidogrel vs aspirin

Physicians Health Study, 1989 - aspirin vs placebo

British Doctor’s Trial, 1988 - aspirin vs no treatment



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of aspirin
    		•  

    British Doctor’s Trial study, 1988

    Treatments

    Studied treatment aspirin 500 mg/d
    Control treatment no aspirin

    Patients

    Patients Healthy men

    Method and design

    Randomized effectives 3429 / 1710 (studied vs. control)
    Design Parallel groups
    Blinding open
    Geographic area UK


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Coronary event

    169 / 3429
         88 / 1710
         0,96 [0,75;1,23]

    stroke (fatal and non fatal)

    91 / 3429
         39 / 1710
         1,16 [0,80;1,69]

    Haemmorhagic stroke

    13 / 3429
         6 / 1710
         classic 1,08 [0,41;2,84]

    Major gastrointestinal bleeding

    20 / 3429
         10 / 1710
         classic 1,00 [0,47;2,13]

    Non fatal MI

    80 / 3429
         41 / 1710
         0,97 [0,67;1,41]

    ischemic stroke

    21 / 3429
         7 / 1710
         classic 1,50 [0,64;3,51]

    Coronary death

    89 / 3429
         47 / 1710
         0,94 [0,67;1,34]

    All cause death

    270 / 3429
         151 / 1710
         0,89 [0,74;1,08]

    Cardiovascular events

    289 / 3429
         147 / 1710
         0,98 [0,81;1,19]

    Cardiovascular death

    148 / 3429
         79 / 1710
         0,93 [0,72;1,22]

    Non fatal stroke

    61 / 3429
         27 / 1710
         1,13 [0,72;1,77]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Coronary event 169 / 3429 (4,9%) 88 / 1710 (5,1%) 0,96 [0,75;1,23]    
    stroke (fatal and non fatal) 91 / 3429 (2,7%) 39 / 1710 (2,3%) 1,16 [0,80;1,69]    
    Haemmorhagic stroke 13 / 3429 (0,4%) 6 / 1710 (0,4%) 1,08 [0,41;2,84]    
    Cardiovascular events 289 / 3429 (8,4%) 147 / 1710 (8,6%) 0,98 [0,81;1,19]    
    Non fatal MI 80 / 3429 (2,3%) 41 / 1710 (2,4%) 0,97 [0,67;1,41]    
    ischemic stroke 21 / 3429 (0,6%) 7 / 1710 (0,4%) 1,50 [0,64;3,51]    
    Coronary death 89 / 3429 (2,6%) 47 / 1710 (2,7%) 0,94 [0,67;1,34]    
    All cause death 270 / 3429 (7,9%) 151 / 1710 (8,8%) 0,89 [0,74;1,08]    
    Major gastrointestinal bleeding 20 / 3429 (0,6%) 10 / 1710 (0,6%) 1,00 [0,47;2,13]   0 
    Cardiovascular death 148 / 3429 (4,3%) 79 / 1710 (4,6%) 0,93 [0,72;1,22]    
    Non fatal stroke 61 / 3429 (1,8%) 27 / 1710 (1,6%) 1,13 [0,72;1,77]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Coronary event 4,93% 5,15% -2,2‰
    stroke (fatal and non fatal) 2,65% 2,28% 3,7‰
    Haemmorhagic stroke 3,79‰ 3,51‰ 0,3‰
    Cardiovascular events 8,43% 8,60% -1,7‰
    Non fatal MI 2,33% 2,40% -0,6‰
    ischemic stroke 6,12‰ 4,09‰ 2,0‰
    Coronary death 2,60% 2,75% -1,5‰
    All cause death 7,87% 8,83% -9,6‰
    Major gastrointestinal bleeding 5,83‰ 5,85‰ -0,0‰
    Cardiovascular death 4,32% 4,62% -3,0‰
    Non fatal stroke 1,78% 1,58% 2,0‰


    Reference(s)

    Trials register # NA
    • Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. Randomised trial of prophylactic daily aspirin in British male doctors.. Br Med J (Clin Res Ed) 1988 Jan 30;296:313-6
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend